Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment

Reuters11-10

Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment

Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582875531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582875531","market":"us","top_or_hot":-1,"title":"Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065731478.USD","symbol_name":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLb4cFfk:1","article_id":"2582875531","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582875531","pubTimestamp":1762777016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.Disclaimer: This news brief wa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","GKOS":"Glaukos Corp","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备"},"translate_title":"Glaukos推出富有远见的眼病治疗战略和创新平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GKOS":0.9},"content_text":"Glaukos Unveils Visionary Strategies and Innovation Platforms for Eye Disease Treatment\n    \n\n        Glaukos Corporation has released a presentation outlining its core growth strategies and recent advancements. The company highlighted its focus on innovation, with significant investment in research and development since 2018 and the expansion of its pipeline to 14 disclosed ocular programs in 2025. Glaukos showcased five novel technology platforms, including micro-scale surgical devices, sustained-release and bio-activated pharmaceuticals, transdermal pharmaceuticals, and bio-erodible intravitreal therapies. The presentation covered four therapeutic areas: glaucoma, rare diseases such as keratoconus, anterior segment conditions, and posterior segment diseases. Key commercial catalysts for 2025-26 include methodical launches of interventional glaucoma therapies and new treatments for keratoconus. The company also reported progress in expanding market access and clinical evidence for its products. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582875531","isCrawlerRequest":true}